Abiomed closed the most recent trading day at $330.35, moving -0.83% from the previous trading session. This change was narrower than the S&P 500's daily loss of 1.73%. At the same time, the Dow lost 1.19%, and the tech-heavy Nasdaq lost 2.07%.
Prior to today's trading, shares of the maker of heart devices had lost 24.79% over the past month. This has lagged the Medical sector's loss of 8.88% and the S&P 500's loss of 7.09% in that time.
Investors will be hoping for strength from ABMD as it approaches its next earnings release, which is expected to be November 1, 2018. In that report, analysts expect ABMD to post earnings of $0.73 per share. This would mark year-over-year growth of 65.91%. Our most recent consensus estimate is calling for quarterly revenue of $175.32 million, up 32% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.63 per share and revenue of $768.18 million. These totals would mark changes of +88.98% and +29.38%, respectively, from last year.
Any recent changes to analyst estimates for ABMD should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. ABMD is currently sporting a Zacks Rank of #1 (Strong Buy).
Digging into valuation, ABMD currently has a Forward P/E ratio of 71.89. For comparison, its industry has an average Forward P/E of 32.04, which means ABMD is trading at a premium to the group.
We can also see that ABMD currently has a PEG ratio of 2.66. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.68 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 151, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Image: Bigstock
Abiomed (ABMD) Stock Moves -0.83%: What You Should Know
Abiomed closed the most recent trading day at $330.35, moving -0.83% from the previous trading session. This change was narrower than the S&P 500's daily loss of 1.73%. At the same time, the Dow lost 1.19%, and the tech-heavy Nasdaq lost 2.07%.
Prior to today's trading, shares of the maker of heart devices had lost 24.79% over the past month. This has lagged the Medical sector's loss of 8.88% and the S&P 500's loss of 7.09% in that time.
Investors will be hoping for strength from ABMD as it approaches its next earnings release, which is expected to be November 1, 2018. In that report, analysts expect ABMD to post earnings of $0.73 per share. This would mark year-over-year growth of 65.91%. Our most recent consensus estimate is calling for quarterly revenue of $175.32 million, up 32% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.63 per share and revenue of $768.18 million. These totals would mark changes of +88.98% and +29.38%, respectively, from last year.
Any recent changes to analyst estimates for ABMD should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. ABMD is currently sporting a Zacks Rank of #1 (Strong Buy).
Digging into valuation, ABMD currently has a Forward P/E ratio of 71.89. For comparison, its industry has an average Forward P/E of 32.04, which means ABMD is trading at a premium to the group.
We can also see that ABMD currently has a PEG ratio of 2.66. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.68 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 151, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.